Slowing progressive chronic diseases requires substituting clinical endpoints with surrogate biomarkers.
To accelerate market access for progressive kidney and endocrine conditions, regulatory systems are clearing therapies based on early surrogate biomarkers, postponing final clinical verification.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Vertex's BLA for a progressive kidney condition relies on proteinuria reduction, a validated surrogate endpoint, to accelerate its market entry.
The FDA leveraged accelerated approval based on a surrogate biomarker to delay pancreatic functional decline, requiring a follow-up trial to confirm real-world clinical efficacy.
Sanofi secured an accelerated regulatory approval for a childhood diabetes therapy by substituting traditional clinical endpoints with a surrogate molecular biomarker.
Vera secured accelerated approval for its progressive kidney therapy using a surrogate biomarker of kidney damage instead of waiting for clinical decline endpoints.
Otsuka is converting its early biomarker-based approval into traditional full approval using two-year clinical kidney function slope data.
It illustrates the regulatory willingness to clear progressive kidney therapies using early surrogate biomarkers, postponing final verification of kidney function.
Accelerated approval was granted for this progressive kidney disease by leveraging an early surrogate endpoint ahead of long-term validation.
Trutakna was cleared under the accelerated pathway based on the surrogate endpoint of proteinuria, delaying full approval until final eGFR data is evaluated.
The FDA granted accelerated approval to the kidney therapy based on the reduction of a surrogate biomarker rather than waiting for long-term clinical data on kidney function.
Regulators cleared Bristol Myers Squibb's chronic multiple myeloma therapy using a deep surrogate biological response to accelerate market access.
The FDA's landmark approval of Zenbexus based on MRD-negativity establishes the substitution of clinical outcomes with surrogate biomarkers in progressive chronic disease settings.